Fountoulakis K N, Vieta E, Sanchez-Moreno J, Kaprinis S G, Goikolea J M, Kaprinis G S
3rd Department of Psychiatry, Aristotle University of Thessaloniki, Greece.
J Affect Disord. 2005 May;86(1):1-10. doi: 10.1016/j.jad.2005.01.004.
The development of treatment guidelines emerged as an important element so as to standardize treatment and to provide clinicians with algorithms, which would be able to carry research findings to the everyday clinical practice.
The MEDLINE was searched with the combination of each one of the key words 'mania', 'manic', 'bipolar', 'manic-depression', 'manic-depressive' with 'treatment guidelines'.
The search was updated until March 1st, 2004 and returned 224 articles. Twenty-seven papers concerning the publication of treatment algorithms were traced.
Despite supposedly being evidence-based, guidelines for the treatment of bipolar disorder vary significantly across committees or working groups. Overall, however, at the first stage of the mania/hypomania algorithm, monotherapy with lithium, divalproex sodium or olanzapine is generally recommended. At latter stages combination therapy is strongly recommended. It is clearly stated that in bipolar depression antidepressants should be used only in combination with antimanic agents in order to avoid switching of phases. During the maintenance phase all patients should receive antimanic agents, while some may need the addition of antidepressants. The most recent guidelines emphasize the use of atypical antipsychotics for mania and lamotrigine for depression. The main problem with guidelines is that they are rapidly outdated and that the evidence base relies mainly on registration monotherapy trials that hardly reflect treatment in routine clinical conditions.
Treatment guidelines may be useful to avoid non-evidence-based treatment decisions, but they are quickly out-of-date and may not fully apply to the clinical setting. The more recent guidelines point the value of atypical antipsychotics, lithium, and valproate in the treatment of mania; the role of lithium, lamotrigine, and olanzapine as options for maintenance therapy; and the scarcity of options for the treatment of bipolar depression. Psychoeducation is also supported by most guidelines as an adjunctive treatment.
治疗指南的制定成为标准化治疗并为临床医生提供算法的重要因素,这些算法能够将研究成果应用于日常临床实践。
在MEDLINE数据库中,将关键词“躁狂”“躁狂的”“双相”“躁郁症”“躁郁的”分别与“治疗指南”进行组合检索。
检索更新至2004年3月1日,共返回224篇文章。追踪到27篇关于治疗算法出版物的论文。
尽管双相情感障碍的治疗指南理应基于证据,但不同委员会或工作组的指南差异显著。然而总体而言,在躁狂/轻躁狂算法的第一阶段,通常推荐使用锂盐、丙戊酸钠或奥氮平进行单药治疗。在后期阶段,强烈推荐联合治疗。明确指出,在双相抑郁中,抗抑郁药应仅与抗躁狂药联合使用,以避免相转换。在维持阶段,所有患者都应接受抗躁狂药治疗,而一些患者可能需要加用抗抑郁药。最新指南强调使用非典型抗精神病药物治疗躁狂,使用拉莫三嗪治疗抑郁。指南的主要问题在于它们很快过时,且证据基础主要依赖于注册的单药治疗试验,这些试验几乎无法反映常规临床情况下的治疗。
治疗指南可能有助于避免无证据支持的治疗决策,但它们很快过时,可能无法完全适用于临床环境。最新指南指出了非典型抗精神病药物、锂盐和丙戊酸盐在治疗躁狂中的价值;锂盐、拉莫三嗪和奥氮平作为维持治疗选择的作用;以及双相抑郁治疗选择的匮乏。大多数指南也支持将心理教育作为辅助治疗。